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Abstract: Cardiovascular function is modulated by neuronal transmitters, circulating hormones, 
and factors that are released locally from tissues. Urotensin II (UII) is an 11 amino acid peptide 
that stimulates its’ obligatory G protein coupled urotensin II receptors (UT) to modulate car-
diovascular function in humans and in other animal species, and has been implicated in both 
vasculoprotective and vasculopathic effects. For example, tissue and circulating concentrations 
of UII have been reported to increase in some studies involving patients with atherosclerosis, 
heart failure, hypertension, preeclampsia, diabetes, renal disease and liver disease, raising the 
possibility that the UT receptor system is involved in the development and/or progression of 
these conditions. Consistent with this hypothesis, administration of UT receptor antagonists to 
animal models of cardiovascular disease have revealed improvements in cardiovascular remodel-
ling and hemodynamics. However, recent studies have questioned this contributory role of UII 
in disease, and have instead postulated a protective effect on the cardiovascular system. For 
example, high concentrations of circulating UII correlated with improved clinical outcomes in 
patients with renal disease or myocardial infarction. The purpose of this review is to consider 
the regulation of the cardiovascular system by UII, giving consideration to methodologies for 
measurement of plasma concentrations, sites of synthesis and triggers for release.
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Introduction
Urotensin II (UII) is an 11 amino acid peptide derived from larger 124 and 139 amino 
acid alternative splicing variants (prepro-UII) (Figure 1) (Coulouarn et al 1998; Ames 
et al 1999). The cDNA of a distinct gene encoding a 119 amino acid precursor protein 
was also cloned, and the precursor protein was found to generate a biologically active, 
8 amino acid peptide designated urotensin II-related peptide (URP) (Figure 1) (Sugo 
et al 2003). UII and URP have a homologous Cys-Cys ring structure (CFWKYC), and 
both peptides bind to, and activate a 389 amino acid Gαq-coupled receptor (UT) which 
shares 75% sequence homology with the rat UT receptor, GPR14 (Ames et al 1999).
Cardiovascular effects of UII include positive inotropy in human and rat myo-
cardium (Russell et al 2001; Russell and Molenaar 2004; Gong et al 2004), although 
negative inotropy has been reported in canine cardiomyocytes (Morimoto et al 2002) 
and in rabbit papillary muscle (Fontes-Sousa et al 2007). UII stimulates vasocon-
striction or vasodilation depending on the vascular bed and on the condition of the 
endothelium (Douglas et al 2004a), and vascular smooth muscle cell proliferation, 
having synergistic interaction with mildly oxidized low density lipoprotein (Sauzeau 
et al 2001; Watanabe et al 2006a). Remodeling changes also include cardiomyocyte 
hypertrophy in the face of elevated expression of UT receptors (Tzanidis et al 2003; 
Onan et al 2004), and collagen synthesis (Tzanidis et al 2003). The UII/ UT receptor-system 
is expressed widely within the cardiovascular system, and expression is upregulated 
in human cardiovascular disease states, including congestive heart failure, essential 
hypertension, coronary artery disease, type II diabetes, and diabetic nephropathy (Zhu 
et al 2006). The use of recently developed nonpeptide UT receptor antagonists has Vascular Health and Risk Management 2008:4(4) 776
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progressed our understanding of the role of UII in the car-
diovascular system. Infusion of UT receptor antagonists into 
animal models of cardiovascular disease has led to improve-
ments in hemodynamics and cardiovascular remodeling, 
suggesting that UII is involved in the pathogenesis and/or 
progression of disease.
In contrast to the correlative studies above, plasma UII 
concentrations were found to be inversely related to markers 
of sympathetic drive, namely plasma norepinephrine and 
neuropeptide Y, and heart rate in patients with end-stage renal 
disease, suggesting that UII may have a protective function 
under certain circumstances (Mallamaci et al 2005; Zoccali 
et al 2006). In support of this supposition, plasma UII concen-
trations were measured and found to be higher in patients with 
end-stage renal disease who were free of cardiovascular events 
over a follow-up period of 0.07–5.8 years, compared with 
patients who experienced one or more cardiovascular events in 
the follow-up period (Zoccali et al 2006). The authors of this 
study speculated on a restorative effect of UII on endothelial 
function, where endothelial dysfunction is characteristic in 
patients with end-stage renal disease. Consistent with this 
hypothesis, plasma UII concentrations were inversely cor-
related with plasma ﬁ  brinogen and intracellular adhesion 
molecule-1, biomarkers of cardiovascular disease and endo-
thelial activation, in patients with end-stage renal disease 
(Mallamaci et al 2006). Similar inverse correlations of UII 
concentrations and clinical outcomes were made in patients 
with acute myocardial infarction. Plasma UII concentrations 
were raised in patients with an acute myocardial infarction, 
where patients with levels below the median value fared worse 
in terms of survival, and adverse clinical outcomes, such as 
readmission to hospital with heart failure and requirement for 
urgent revascularization, than patients with concentrations 
above the median value (Khan et al 2007).
This review examines the role of UII in health and disease, 
giving consideration to methodologies for UII measurement. 
The effects of UII on cardiovascular regulation, and the 
importance of the endothelium in functional responses to UII 
will be discussed, as well as sites of synthesis and triggers for its’ 
release. For discussion of the functional role of UII in the various 
organ systems, readers are directed to previous review articles 
(Douglas et al 2004a; Russell 2004; McDonald et al 2007).
Evidence implicating urotensin
II as an endogenous mediator
of cardiovascular disease
In vivo and in vitro studies suggest that UII has a role 
in myocardial and vascular remodeling associated with 
cardiovascular disease. These studies have typically involved 
administration of exogenous UII to animals to observe 
changes in cardiac or vascular structure and function, or 
treatment of cell cultures with UII to observed effects on cell 
growth and protein production. For example, incubation of 
cultured neonatal rat cardiac ﬁ  broblasts with UII (100 nM, 
24 h) resulted in a proﬁ  brogenic response with increased 
expression of ﬁ  bronectin, and α1(I) and α1(III) procollagen 
mRNA, and stimulation of collagen synthesis (Tzanidis 
et al 2003). UII did not produce a hypertrophic response 
in cultured neonatal rat cardiomyocytes, although this was 
observed in cells that were transfected with recombinant UT 
receptors, suggesting that expression levels were normally 
below that required to trigger the cell growth response 
(Tzanidis et al 2003; Onan et al 2004). Interestingly, rats 
that were treated with UII (5 μg/kg intravenously for 1 day 
and then 1.5 μg/kg subcutaneously twice daily for 6 days) 
together with the β-adrenoceptor agonist isoproterenol 
(5 mg/kg/day for 7 days), showed a greater increase in 
heart weight to body weight ratio that was consistent with 
myocardial hypertrophy, than animals treated with isopro-
terenol only (Zhang et al 2007). Increased expression of UT 
receptor mRNA was detected in hearts obtained from rats 
treated with isoproterenol compared to vehicle (Zhang et al 
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Figure 1 Amino acid sequence for mature, biologically active human urotensin II (UII) (Coulouarn et al 1998; Ames et al 1999), and human urotensin II-related peptide 
(URP) (Sugo et al 2003).Vascular Health and Risk Management 2008:4(4) 777
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2007), and this may explain the ability of UII to stimulate 
the hypertrophic response in these rats. Studies such as the 
ones described above, that involve exposure of tissues or 
cells to high concentrations of exogenously administered 
UII contribute to our understanding of possible pathogenic 
changes that occur in disease.
Elevated circulating concentrations of UII-like immu-
noreactivity have been detected in patients with various 
cardiovascular disease states, including heart failure (Ng et al 
2002; Richards et al 2002; Russell et al 2003; Lapp et al 
2004; Gruson et al 2006), hypertension (Cheung et al 2004; 
Suguro et al 2007), carotid atherosclerosis (Suguro et al 
2007), preeclampsia and eclampsia (Balat et al 2005), renal 
dysfunction (Totsune et al 2001) and diabetes mellitus 
(Totsune et al 2003). The elevated plasma concentrations 
of UII are consistent with local production by cells and sub-
sequent release of UII into the circulation. Indeed, several 
studies have identiﬁ  ed increased expression of UII in tis-
sues in patients with cardiovascular disease. For example, 
immunoreactive staining for UII was not evident in normal 
coronary arteries (Hassan et al 2005), but staining was 
observed in endothelial cells of human atherosclerotic coro-
nary arteries (Maguire et al 2004; Hassan et al 2005). Intense 
immunoreactive staining was also observed in regions of the 
plaque containing inﬁ  ltrating inﬂ  ammatory cells (Maguire 
et al 2004; Hassan et al 2005), and this was consistent with 
changes in mRNA expression determined by in situ hybrid-
ization (Hassan et al 2005). While UII was either undetected, 
or weak immunoreactive staining only was observed within 
human cardiomyocytes from subjects with nonfailing hearts, 
immunoreactive staining of greater intensity was detected 
in cardiomyocytes from patients with end-stage congestive 
heart failure (Douglas et al 2002). Together these ﬁ  ndings 
indicate upregulation of UII expression by cardiovascular 
tissues, leading to possible increased release of UII into the 
circulation, in cardiovascular disease. Until recently, it has 
been difﬁ  cult to delineate whether elevated circulating and 
tissue concentrations of UII are markers of disease only, or 
whether they are additionally, intrinsically implicated in the 
pathogenesis of disease.
The production of nonpeptide UT receptor antagonists in 
recent years has allowed investigators to assess the role of 
endogenous UII in cardiovascular disease (Watanabe et al 
2006b). Prevention of pathological changes associated with 
elevated UII concentrations after administration of a UT 
receptor antagonist provides strong evidence for a role of 
UII in the development and progression of disease. Studies 
have investigated the ability of the UT receptor antagonist 
SB-611812 to attenuate cardiac dysfunction in a rat model of 
coronary artery ligation (Bousette et al 2006a). SB-611812 
is a nonpeptide UT receptor antagonist (pA2 = 6.59 in rat 
aortic contractile experiments) that has no intrinsic activity 
at UT receptors (Bousette et al 2006a). In this study, rats 
underwent 8 week ligation of the left anterior descending 
coronary artery or sham surgery, and were treated with SB-
6118128 (30 mg/kg/day) or vehicle for 8 weeks. The ani-
mals that were treated with the antagonist exhibited marked 
reductions in cardiomyocyte hypertrophy and ventricular 
dilatation, reduced pulmonary edema, and improvements in 
myocardial function as evidenced by signiﬁ  cant reductions 
in left ventricular end diastolic pressure, right ventricular 
systolic pressure, and central venous pressure compared 
to vehicle treated animals (Bousette et al 2006a). In the 
same coronary artery ligation model, treatment of animals 
with SB-6118128 caused a reduction in interstitial ﬁ  brosis 
within the noninfarct zone of the left ventricle compared with 
vehicle-treated animals (Bousette et al 2006b). Together, the 
studies identify improved cardiac function and attenuated 
cardiac remodeling in the coronary artery ligation model 
when UT receptors were blocked, and this correlated with 
improved survival rates over the 8 week treatment period 
(Bousette et al 2006a).
In a rat, balloon angioplasty model of restenosis, rats 
were treated with SB-611812 (30 mg/kg/day) or vehicle for 
28 days to determine the effect of the antagonist on intimal 
thickening (Rakowski et al 2005). Rats that underwent 
balloon angioplasty and were treated with the UT receptor 
antagonist had signiﬁ  cantly less intimal thickening than 
vehicle-treated animals (Rakowski et al 2005), indicating 
that endogenous UII contributes to the pathogenic effect 
on blood vessel remodeling. ACT-058362 (palosuran) is a 
nonpeptide, competitive UT receptor antagonist that binds to 
two populations of UII binding sites (KD = 1.9 pM, 155 pM) 
in CHO cells expressing human UT receptors (Clozel et al 
2004). Interestingly, the same study showed that palosuran 
produced an apparent noncompetitive antagonism of UII-
mediated contraction of isolated rat aorta. When palosuran 
(300 mg/kg/day) or vehicle was administered to a strepto-
zotocin rat model of diabetes, increased glucose tolerance 
and decreased proteinuria were observed (Clozel et al 2006). 
Survival rates in the diabetic rats treated for 25 weeks with 
palosuran were markedly greater than for rats treated with 
vehicle, and this was attributed to antihyperglycemic effects, 
attenuation of sympathomimetic effects of UII, and preven-
tion of diabetic nephropathy (Clozel et al 2006). Preliminary 
studies involving administration of palosuran to healthy Vascular Health and Risk Management 2008:4(4) 778
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human subjects have been conducted, and the antagonist was 
found to be well tolerated and rapidly absorbed (Sidharta 
et al 2005). The antagonist has now been administered to 
macroalbuminuric diabetic patients at a dose of 125 mg, twice 
daily for 13.5 days, and results indicate no change in renal 
hemodynamics and a 24.3% reduction in urinary albumin 
excretion (Sidharta et al 2006).
Critical role of the endothelium
in vascular effects of UII in health 
and disease
UII is a more potent vasoconstrictor (pEC509.3 compared with 
8.6 in human small coronary arteries; Maguire et al 2004) 
and a more potent cardiostimulant (pEC50 9.5 compared 
with 8.5 in human atrial trabeculae; Russell et al 2003), than 
endothelin-1. When UII was infused into the brachial artery 
of healthy, normotensive, nonsmoking subjects, a dose-
dependent fall in forearm blood ﬂ  ow was observed (Böhm 
and Pernow 2002), indicating vasoconstriction. These ﬁ  nd-
ings were consistent with in vitro experiments, where it was 
identiﬁ  ed that UII caused potent vasoconstriction in a variety 
of human isolated blood vessel preparations (Maguire et al 
2000, 2004). The infusion of UII at a rate of 300 pmol min−1 
into healthy subjects caused either a reduction in forearm 
blood ﬂ  ow (Böhm and Pernow 2002), or no change in blood 
ﬂ  ow (Wilkinson et al 2002), and no change in hemodynamic 
response (Affolter et al 2002). Possible contributing factors 
to the divergent ﬁ  ndings are patient-to-patient variability 
with respect to vascular responsiveness to UII (Maguire 
et al 2000), subject age and possible inclusion of smokers in 
some of the studies (Affolter et al 2002; Böhm and Pernow 
2002; Wilkinson et al 2002). It has been noted that the rate 
of dissociation of UII from UT receptors is slow, leading 
to prolonged activation of receptors by UII (Douglas et al 
2004b). UT receptors have been shown to undergo rapid 
sequestration following incubation of HEK293 cells with 
UII, with trafﬁ  cking of receptors from the plasma membrane 
to endosomes (Giebing et al 2005). It has been suggested 
that as a result of chronic activation and sequestration of 
UT receptors under normal physiological conditions, the 
UT receptor system is “functionally silent”, and this could 
explain the above lack of responsiveness of exogenous UII 
in healthy human subjects (Lambert 2007).
There is strong evidence to indicate that stimulation of UT 
receptors on animal vascular endothelial cells can trigger the 
release of nitric oxide and prostaglandins that would serve 
to balance direct contractile effects of UII on smooth muscle 
(Bottrill et al 2000; Katano et al 2000; Gray et al 2001; Zhang 
et al 2003; Ishihata et al 2005; Gardiner et al 2006; Lacza and 
Busija 2006). For example, studies in newborn pig showed 
UII-stimulated vasodilation of pial arteries (i.d. 100–120 μm) 
that was sensitive to the nitric oxide synthase inhibitor, 
Nω-nitro-L-arginine-methyl ester (L-NAME) (Lacza and 
Busija 2006). In Langendorff-perfused hearts obtained from 
young (2–3 month old) rats, UII increased coronary ﬂ  ow, 
and this was inhibited by the nitric oxide synthase inhibitor, 
NG-nitro-L-arginine and by the cyclooxygenase inhibitor, 
diclofenac (Ishihata et al 2005), suggesting UII-mediated 
vasodilation by nitric oxide and prostaglandins. Indeed, this 
study also revealed that administration of UII to the perfused 
rat hearts increased concentrations of nitric oxide and the sta-
ble metabolite of prostacylin, PGF1α in the coronary efﬂ  uent 
(Ishihata et al 2005). Studies using precontracted rat isolated 
small mesenteric arteries showed that endothelial-derived 
hyperpolarizing factor also contributes to the vasorelaxant 
response of UII (Bottrill et al 2000).
Subject- and regional-variability exists for responsiveness 
of human blood vessels to UII. Human endothelial-denuded 
isolated coronary, mammary and radial arteries, and saphe-
nous and umbilical veins contract when exposed to UII 
(Maguire et al 2000, 2004; Russell et al 2001). UII did not 
contract human mammary artery or saphenous vein when the 
endothelium was intact (Hillier et al 2001), suggesting that 
the endothelial cells release a dilator substance that opposes 
smooth muscle contraction. In endothelial-intact human small 
muscular pulmonary arteries, UII produced vasorelaxant 
responses (Stirrat et al 2001), and in resistance vessels UII 
produced either a relaxant response (Stirrat et al 2001) or 
no response (Hillier et al 2001). While the contribution of 
prostaglandins or endothelial-derived hyperpolarizing factor 
to relaxation of human blood vessels exposed to UII remains 
to be determined, it is likely that nitric oxide has a pivotal 
role. UII did not modulate vascular tone in human isolated 
pulmonary arteries (i.d. 250 μm), however 3/10 blood vessels 
contracted when vessels were exposed to UII in the pres-
ence of L-NAME (MacLean et al 2000), indicating that a 
contractile response could be unmasked in some vessels only 
when nitric oxide production was inhibited. This study using 
human isolated vessels differs to an in vivo rat study where 
inhibition of nitric oxide or prostaglandins attenuated the 
vasorelaxant response to UII, but did not unmask a contrac-
tile response (Gardiner et al 2006). In anatomically normal 
segments of human coronary artery that were removed from 
patients with coronary atherosclerosis, immunoreactive stain-
ing for UII was colocalized with immunoreactive staining 
for endothelial nitric oxide synthase in the endothelial cells Vascular Health and Risk Management 2008:4(4) 779
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(Hassan et al 2005), indicating possible local dilator effects 
of UII. UII binding sites have previously been localized 
to vascular endothelial cells (Douglas et al 2002), and it is 
therefore likely that UII stimulates nitric oxide-dependent 
vascular relaxation in an autocrine or paracrine manner to 
oppose contractile effects of UII on smooth muscle.
Recent evidence suggests that endothelial function may 
be a key determinant of changes in vasomotor tone to UII in 
vivo. UII was administered by iontophoresis to forearm skin 
microvessels in healthy subjects and in patients with chronic 
heart failure, and blood ﬂ  ow in these vessels was measured 
using laser Doppler velocimetry (Lim et al 2004). In healthy 
subjects, UII caused an increase in blood ﬂ  ow indicating vaso-
relaxation, while in patients with heart failure UII caused a 
decrease in blood ﬂ  ow, indicating vasoconstriction (Lim et al 
2004). The differences are attributed to impaired endothelial 
function in patients with heart failure, where endothelial 
cells normally produce nitric oxide and prostacyclin which 
contribute to reduced vascular tone. Loss or dysfunction of 
the endothelial cells may therefore result in an imbalance 
in vascular responsiveness to UII, favoring the contractile 
response over the relaxant response. This hypothesis is 
supported by a nonsigniﬁ  cant trend for reduced vasodilator 
response to the endothelium-dependent agonist, acetylcholine, 
but no diminution in response to the endothelium-independent 
dilator, sodium nitroprusside in the heart failure cohort (Lim 
et al 2004). A similar study using iontophoresis compared 
blood ﬂ  ow in the microcirculation of normotensive subjects 
and hypertensive patients, where a vasodilator response to UII 
was observed in the microvessels of normotensive subjects 
while patients with hypertension responded with a vasocon-
strictor response (Sondermeijer et al 2005). Endothelial cell 
dysfunction is known to be associated with hypertension, as 
evidenced by diminished acetylcholine-induced relaxation of 
norepinephrine pre-constricted small subcutaneous arteries 
(Wang et al 2003). Despite this observation, acetylcholine and 
sodium nitroprusside produced similar vasodilator responses 
in the iontophoresis study (Sondermeijer et al 2005), suggest-
ing that only very subtle loss of endothelial function may be 
required to generate marked differences in vascular tone in 
hypertensive patients, if indeed endothelial dysfunction is 
responsible for the observed contrasting responses to UII in 
these patients.
Considerations for measurement 
of UII
Patients with cardiovascular disease are often at risk of 
development of multiple complications, where for example 
patients with peripheral arterial disease have an increased 
risk for development of coronary artery disease and diabetes 
mellitus. It is therefore imperative that cohorts of patients are 
well characterized with respect to their condition in order to 
avoid possible confounding inﬂ  uences on the measurement 
of plasma UII concentrations. In comparing UII concen-
trations in patients with hypertension with normotensive 
controls, Suguro and colleagues (2007) excluded patients 
who had co-existing disease known to be associated with 
raised UII concentrations, including coronary artery dis-
ease, heart failure, diabetes mellitus or renal dysfunction. 
UII concentrations were elevated in the hypertensive group 
(7.9 ± 7.6 ng/ml versus 2.3 ± 1.2 ng/ml; P  0.0001), rep-
resenting a 3.4-fold increase. Through careful selection of 
inclusion and exclusion criteria, these authors were able to 
attribute the elevation of UII to hypertension, differentiating 
other disease states that have been reported to increase blood 
UII concentrations.
UII concentrations have been determined in a variety 
of pathophysiological conditions, comparing values with 
nondisease control subjects, and considerable discrepancies 
have been noted in absolute levels of UII detected. Concen-
trations of UII-like immunoreactivity in control subjects 
who have no evidence of heart failure range from 0.8 pg/ml 
(Gruson et al 2006) to 3290 pg/ml (Krüger et al 2005), and 
in heart failure patients, from 1.5 pg/ml (Gruson et al 2006) 
to 6631 pg/ml (Lapp et al 2004). The differences between 
studies is marked (over 4,000-fold for both control and 
heart failure subjects), and possible explanations for these 
discrepancies are stated below. However, the notion that UII 
concentrations are elevated in patients with heart failure is 
not universally accepted. For example, some studies reported 
increased plasma UII-like immunoreactivity in heart failure 
patients compared to patients with nonfailing hearts, or in the 
studies by Lapp et al 2004, compared with subjects classiﬁ  ed 
as New York Heart Association (NYHA) I, by between 1.5 
and 10-fold (Ng et al 2002; Richards et al 2002; Russell et al 
2003; Lapp et al 2004; Gruson et al 2006), while other stud-
ies found no difference in concentrations between control 
and heart failure patients (Dschietzig et al 2002; Krüger 
et al 2005). Furthermore, studies that identiﬁ  ed elevated 
UII-like immunoreactivity showed either a correlation 
(Lapp et al 2004; Gruson et al 2006) or no correlation in 
concentrations of UII-like immunoreactivity with severity 
of disease as determined by NYHA class (Ng et al 2002; 
Russell et al 2003).
A number of methodological approaches have been 
used to identify plasma UII concentrations, including the Vascular Health and Risk Management 2008:4(4) 780
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use of radioimmunoassay, enzyme immunoassays, and 
immunoluminometric assays from different commercial 
and in-house sources, and this may in part contribute to the 
discrepancies observed. For example, the comparative mea-
surement of plasma UII concentrations in cigarette smokers 
versus nonsmokers was quite different depending on the 
type of assay that was employed. Signiﬁ  cant increases in UII 
concentrations were identiﬁ  ed when a commercially avail-
able radioimmunoassay kit was used (2.62 pg/ml for smokers 
versus 1.67 pg/ml for nonsmokers; median values, P  =  0.034), 
but no difference was detected using an immunoluminomet-
ric assay (Gold et al 2007). Sensitivity of detection was not 
the reason for the discrepancy, as the immunoluminometric 
assay detected UII at 2.4-fold lower concentrations than 
the radioimmunoassay (Gold et al 2007). Antibodies raised 
against UII and that recognize the C-terminal hexapeptide 
amino acid sequence (CFWKYC) do not differentiate UII 
and URP. A reason for discrepant ﬁ  ndings between studies 
that employ different immunoreactive methodologies might 
therefore be attributed to differing concentrations of UII, 
precursor forms of UII, URP, and other unrelated immuno-
reactive peptides. To underline this point, multiple molecules 
containing UII-like immunoreactivity have been detected 
in plasma samples from heart failure patients (Russell et al 
2003), and in culture media of adrenocortical carcinoma cells 
(Takahashi et al 2001).
Veriﬁ  cation of peptide identity is possible with analytical 
instruments such as high performance liquid chromatography 
which can be used to measure peptide retention times, and 
mass spectrometry which provide mass-to-charge ratios as 
a “signature” of the peptide of interest. These technologies 
were used to differentiate a 25 amino acid C-terminal frag-
ment of pro-UII from the mature, 11 amino acid peptide 
(Russell et al 2004). Techniques dependent on immunoreac-
tive discrimination are unlikely to distinguish the precursor 
and mature forms of UII where, for example, the antibody 
raised against UII exhibited 29% cross-reactivity with the 
C-terminal fragment of pro-UII (Russell et al 2003). Plasma 
concentrations of UII-like immunoreactivity were found to 
be elevated in patients with heart failure, although mature 
UII was not identiﬁ  ed in the fractions using HPLC-mass 
spectrometry (Russell et al 2003). These ﬁ  ndings suggest 
increased expression of prepro-UII, prepro-URP, or pro-
teolytic cleavage fragments of the precursor peptides that 
retain the epitopes required for antibody recognition. The 
physiological or pathophysiological signiﬁ  cance of pro-UII 
fragments may be dependent on the enzymatic conversion of 
the fragment to mature UII by the previously characterized 
urotensin-converting enzyme (Russell et al 2004). Consistent 
with this hypothesis, the 25 amino acid C-terminal fragment 
of pro-UII had much reduced potency compared with mature 
UII for cardiostimulatory effects in isolated human right atrial 
trabeculae (Russell et al 2003).
The inability to use antibodies to distinguish UII from 
precursor forms of UII, and in some instances URP, raises 
questions over the physiological and/or pathophysiological 
relevance of observed regulatory changes in UII-like immu-
noreactivity. To address this issue, studies were carried out 
to detect plasma levels of molecules that have afﬁ  nity for UT 
receptors, and that therefore infer biological activity (Aiyar 
et al 2004). Factors in blood and urine were examined for 
their ability to compete with [125I]-UII for binding to monkey 
UT receptors that were expressed in HEK-293 cells. The 
advantage of this approach was that there was no presump-
tion that the competing ligand should exhibit the epitope 
for recognition by UII antibodies. In urine samples, three 
HPLC peaks exhibited competitive binding of compounds for 
[125I]-UII at UT receptors, although only two peaks exhibited 
UII-like immunoreactive compounds by radioimmunoas-
say. One of these peaks was consistent with the presence of 
mature UII, and the other with an immunoreactive species 
that was not mature UII, 4–11, 5–11 or  5–10 analogues of UII, 
or URP. Whether this peak contained the same immunoreac-
tive species identiﬁ  ed in heart failure patients (Russell et al 
2003), is not known. The detection of immunoreactivity that 
is distinct from mature UII may account for the large dis-
crepancies in absolute concentrations of UII-like compounds 
between studies (Aiyar et al 2004). A number of studies, 
including manufacturers of radioimmunoassay kits, have 
shown no detectable cross reactivity of antibodies directed 
against UII to endothelin-1, big endothelin-1, somatostatin, 
angiotensin II, PAMP-20, bradykinin, α-atrial natriuretic 
peptide, calcitonin gene related peptide, adrenomedullin, or 
norepinephrine (Phoenix Pharmaceuticals, Burlingame, CA, 
USA; Lapp et al 2004; Russell et al 2003; Aiyar et al 2004; 
Charles et al 2005), suggesting that these molecules do not 
contribute to the reported discrepancies in results obtained 
from studies using immunoreactive techniques. The third 
peak that did not contain UII-like immunoreactivity but 
exhibited binding in the competition binding assay (Aiyar 
et al 2004) suggests the presence of compounds that have 
afﬁ  nity for UT receptors, but do not contain the obligatory 
amino acid sequence of mature UII. Functional assays would 
be required to determine whether receptor binding observed 
for these compounds also results in receptor activation. If the 
unrelated compounds that bind to UT receptors are indeed Vascular Health and Risk Management 2008:4(4) 781
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found to stimulate UT receptors, then studies based on 
measurement of UII-like immunoreactivity alone may con-
siderably under-estimate the signiﬁ  cance of the UT receptor 
system to cardiovascular function, and possibly the extent 
to which the UT receptor system is regulated in a variety of 
pathophysiological conditions.
What is the source of UII?
Low plasma concentrations of UII in healthy subjects 
have been consistently reported, suggesting that UII does 
not serve as a circulating hormone under normal circum-
stances. Plasma concentrations of UII have been shown 
in many studies to be elevated in cardiovascular disease, 
notwithstanding the considerations for measurement 
of plasma UII mentioned above. Interestingly, several 
studies reported a lack of correlation between plasma 
UII concentration and severity of disease (Ng et al 2002; 
Russell et al 2003), leading Maguire and colleagues (2004) 
to speculate on the possible spill-over of excessive local 
production of UII by tissues into the circulation. The 
spill-over phenomenon has been reported for other peptide 
systems, with evidence for polarized release of endothe-
lin-1 from endothelial cells toward the medial vascular 
smooth muscle cells (Yoshimoto et al 1991; Wagner et al 
1992) and the spill over of endothelin-1 in the pulmonary 
circulation of patients with congestive heart failure 
(Tsutamoto et al 1994). Studies have identiﬁ  ed endothelial 
cells as a source of UII, with expression of prepro-UII 
mRNA in cultured human coronary artery and umbilical 
vein endothelial cells (Totsune et al 2003). Inﬂ  ammatory 
cells are also a likely source of UII, with high levels of 
prepro-UII mRNA expression detected in lymphocytes, 
with between 8–48-fold lower levels detected in mono-
cytes, macrophages and foam cells (Bousette et al 2004). 
Positive immunoreactive staining for UII was also detected 
in inﬂ  ammatory cells within atherosclerotic lesions of 
human aorta and in aortae from patients undergoing repair 
surgery for abdominal aortic aneurysm (Bousette et al 
2004), and in atherosclerotic lesions of human coronary 
artery (Maguire et al 2004; Hassan et al 2005). Expres-
sion of UT receptors in lymphocytes was about 20-fold 
lower than in monocytes and about 13-fold lower than in 
macrophages (Bousette et al 2004), raising the possibil-
ity that UII mediates inﬂ  ammatory cell responses in an 
autocrine and/or paracrine manner.
The increase in circulating UII in cardiovascular disease 
may be attributed in part to increased synthesis and release by 
tissues, or decreased clearance of the peptide. The net produc-
tion of UII within tissues can be gauged by sampling blood in 
vascular beds on either side of the tissue and then measuring 
UII concentrations (Table 1). In patients with congestive 
heart failure, plasma UII concentrations were higher in the 
aortic root than in the pulmonary artery (Russell et al 2003), 
suggesting that UII was being produced in the heart or lungs 
Table 1 Concentration gradients for plasma UII across organ systems. Elevated plasma UII concentrations across tissues is indicative 
of a site of synthesis and release of UII
Site of production  Sample site  Plasma [UII]  P value  Reference (Disease/disease model)
Heart and lungs  PA  38 ± 6 pg/ml  P  0.001  Russell et al 2003 (Congestive heart failure; Human)
 AR  231  ± 69 pg/ml   
Heart and lungs  PA  33 ± 5 pg/ml  P  0.05  Russell et al 2003 (Ischemic cardiomyopathy; Human)
 AR  309  ± 124 pg/ml   
Heart and lungs  PA  130 ± 32 pg/ml  NS  Dschietzig et al 2002 (Severe congestive 
 LV  126  ± 32 pg/ml    heart failure; Human)
Coronary   LV  126 ± 32 pg/ml  NS  Dschietzig et al 2002 (Severe 
vasculature/Heart CS  110  ± 40 pg/ml    congestive heart failure; Human)
Coronary   CA  1.3 ± 0.2 pmol/l  P  0.001  Charles et al 2005 (Right ventricular pacing model
vasculature/heart CS  2.1  ± 0.2 pmol/l    of heart failure; Sheep)
Liver HPV  11.2  ng/ml  P   0.005  Heller et al 2002 (Cirrhosis with ascites; Human)
 HV  13.9  ng/ml   
Kidneys RA  1.8  ± 0.2 pmol/l  P  0.05  Charles et al 2005 (Right ventricular pacing 
 RV  2.3  ± 0.2 pmol/l    model of heart failure; Sheep)
Lower limbs  FA  78 ± 11 pg/ml  NS  Russell et al 2003 (Congestive heart failure; Human)
 FV  55  ± 7 pg/ml   
Lower limbs  FA  1.7 ± 0.2 pmol/l  NS  Charles et al 2005 (Right ventricular pacing 
 FV  1.8  ± 0.2 pmol/l    model of heart failure; Sheep)
Notes: Concentrations of UII were determined from tabulated and graphical representations of data in the cited references.
Abbreviations: UII, urotensin II; PA, pulmonary artery; AR, aortic root; LV, left ventricle; CS, coronary sinus; CA, carotid artery; HPV, hepatic portal vein; HV, hepatic vein;
RA, renal artery; RV, renal vein; FA, femoral artery; FV, femoral vein; NS, not signiﬁ  cant.Vascular Health and Risk Management 2008:4(4) 782
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or both heart and lungs. In that study, a cardiopulmonary 
gradient was detected in patients with ischemic cardiomy-
opathy, with a nonsigniﬁ  cant trend for a gradient in patients 
with nonischemic cardiomyopathy. Possible synthesis and 
release of UII from the heart into the circulation was investi-
gated by measuring UII concentrations across the heart using 
an anaesthetised sheep model (Charles et al 2005). Plasma 
UII concentrations were higher in the carotid artery than the 
coronary sinus, where the arteriovenous gradient suggested 
that the myocardium or coronary vasculature may indeed be 
a site of UII production and secretion. Immunohistochemical 
studies in human heart revealed higher expression levels of 
UII-like immunoreactive staining in the subendocardium than 
in the mid-myocardium or subepicardium of patients with 
congestive heart failure (Douglas et al 2002), suggesting that 
the subepicardium is a source of UII. Together, these ﬁ  ndings 
do not exclude synthesis of UII in the pulmonary tissues, but 
point to possible production within the subendocardium and 
release into the heart chambers.
Other sites of UII production include the liver and the 
kidneys. Samples of blood were taken across the liver in 
patients with chronic liver disease and UII concentrations 
were determined. The ﬁ  ndings revealed higher concentra-
tions of UII in the hepatic vein than in the hepatic portal 
vein (Heller et al 2002). More recently, UII concentrations 
were determined in blood from the femoral and hepatic veins 
in patients with chronic liver disease, and were found to be 
higher in the femoral vein (Kemp et al 2007). Together these 
ﬁ  ndings suggest that the liver is a source of UII production in 
patients with chronic liver disease but that extra-hepatic sites 
may also contribute to the raised plasma concentrations. The 
nature of these other sites is not clear, but it is speculated that 
it may involve the cardiovascular system since widespread 
circulatory changes (altered mean arterial pressure) were also 
noted (Kemp et al 2007). The kidneys are an important site 
for UII production, with evidence for moderate (Coulouarn 
et al 1998) to high levels of human prepro-UII mRNA expres-
sion (Nothacker et al 1999) in this organ. Expression of 
human prepro-UII mRNA is regulated, with negligible levels 
detected in fetal kidney (Coulouarn et al 1998; Nothacker 
et al 1999). In the normal human kidney, high levels of UII-
like immunoreactivity were identiﬁ  ed in epithelial cells of 
the distal convoluted tubules, collecting tubules, collecting 
ducts and proximal convoluted tubules (Shenouda et al 2002). 
UII concentrations were found to be elevated in urine from 
patients with renal tubular disorders compared with controls, 
indicating increased synthesis and secretion from renal epi-
thelial cells, decreased reabsorption or a combination of both 
(Matsushita et al 2001). In some individuals, urinary clearance 
of UII exceeded glomerular ﬁ  ltration rate (Matsushita et al 
2001), indicating that renal tubules are a source of secreted 
UII. In support of the renal epithelium as a site of synthesis, 
UII was detected in the culture perfusate of LLCPK1 porcine 
renal epithelial cells (Matsushita et al 2001). Elevated prepro-
UII mRNA expression was detected in renal biopsies obtained 
from patients with diabetic nephropathy compared to control 
nephrectomy samples. The source of this increased expression 
is likely to be the epithelium, as this tissue showed intense 
UII-like immunoreactivity (Langham et al 2004). UII-like 
immunoreactive staining has been reported in renal capillary 
endothelial cells from control subjects (Shenouda et al 2002), 
and these cells may be a potential source of increased circu-
lating concentrations of UII detected in patients with renal 
dysfunction (Totsune et al 2001). It is interesting to note that 
there was a trend for increased plasma UII concentrations in 
two patients who had undergone previous (6 months since 
removal of tissue) bilateral nephrectomy compared to 29 
patients undergoing hemodialysis for end-stage renal disease 
(Mosenkis et al 2007), underlining the importance of nonrenal 
tissues as additional sources of UII.
What is the stimulus for UII 
release?
Plasma concentrations of UII in the aortic root of patients with 
nonfailing hearts are low, but signiﬁ  cantly elevated in heart 
failure, suggesting that heart failure triggers the increased pro-
duction of UII (Russell et al 2003). Myocardial necrosis occurs 
in ischemic cardiomyopathy, a condition associated with the 
cardiopulmonary gradient of UII mentioned above, and it is 
possible that this is a stimulus for the release of UII into the 
circulation. Necrosis can be identiﬁ  ed by assessment of mor-
phological changes in the heart, and by elevated concentrations 
of biochemical markers in the blood, including Troponin T and 
creatinine kinase (Alpert et al 2000). However, in a study that 
examined UII concentrations in patients with acute coronary 
syndrome, deﬁ  ned as angina lasting more than 20 min together 
with additional evidence of cardiovascular disease (Joyal et al 
2006), no correlation was observed between concentrations of 
plasma UII and troponin T (Joyal et al 2006).
Plasma UII concentrations have been shown to increase 
with increased pressure load, raising the possibility that blood 
pressure is a stimulus for UII release. For example, plasma UII 
concentrations correlated positively with increased systolic 
(Cheung et al 2004; Suguro et al 2007) and diastolic blood 
pressure in patients with hypertension (Cheung et al 2004), 
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and eclampsia (Balat et al 2005), with wedged hepatic venous 
pressure gradient, which is an index of portal pressure, in 
patients with portal hypertension (Heller et al 2002), and with 
increased left ventricular end diastolic pressure in patients 
with ischemic cardiomyopathy (Lapp et al 2004). Concentra-
tions of UII in the cerebrospinal ﬂ  uid of hypertensive patients 
also correlated positively with mean arterial blood pressure 
(Thompson et al 2003). As indicated above, studies using 
UT receptor antagonists will be instrumental in differentiat-
ing UII as a marker of disease and UII as a contributor to the 
pathogenesis or progression of disease (Watanabe et al 2006b). 
It is of interest therefore that gene deletion of UT receptors 
in mice produced no change in mean arterial blood pressure 
compared to control mice (Behm et al 2003). UII caused only 
a small contractile response in aortae from control mice (17% 
of 60 mM KCl) and no response in aortae from UT receptor 
knockout mice (Behm et al 2003). It is thus possible that the 
failure to detect an altered pressure response in the knockout 
mouse model is attributed to the low contractile efﬁ  cacy of 
UII in the vascular tissue of this species.
Not all studies showed a positive correlation between 
blood pressure and UII concentrations. For example, a 
negative correlation was observed between plasma UII con-
centrations and mean arterial pressure in patients with acute 
coronary syndrome and stable coronary artery disease (Joyal 
et al 2006). In contrast to the positive correlations between 
pressure and UII concentrations described above, Dschietzig 
and colleagues (2001) showed that neither shear stress nor 
perfusion pressure were stimuli for UII production in cultures 
of bovine pulmonary artery endothelial cells. These investiga-
tors used a specially designed ﬂ  ow chamber that was capable 
of adjusting shear stress and perfusion pressure independently, 
and they found that both prepro-UII mRNA expression and 
UII secretion decreased in the endothelial cells with increas-
ing perfusion pressure. The effect of perfusion pressure on 
the UII system identiﬁ  ed in this study was different to that 
on the endothelin system where increased pressure stimulated 
increased prepro-endothelin-1 mRNA expression from bovine 
pulmonary artery endothelial cells (Dschietzig et al 2001) and 
increased secretion of endothelin-1 from human umbilical 
vein endothelial cells (Hishikawa et al 1995). If UII release 
is triggered by elevated blood pressure, then UII concentra-
tions would be expected to be lower in hypertensive patients 
whose blood pressure is controlled by antihypertensive 
medication compared with untreated hypertensive patients. 
Cheung and colleagues (2004) observed no difference in UII 
concentrations for 37 patients with essential hypertension who 
were treated with antihypertensive medication compared to 
25 untreated patients with essential hypertension, although 
blood pressure was not reported for the treated and untreated 
cohorts. Although UII concentrations were signiﬁ  cantly lower 
in 72 patients with end-stage renal disease being treated with 
antihypertensive medication compared to 119 patients with 
end-stage renal disease who did not receive antihypertensive 
medication (Mallamaci et al 2006), blood pressures in each 
cohort were also not reported. It is thus not known whether 
reduced blood pressure or an effect of antihypertensive 
medication contributed to the decrease in UII concentra-
tions. Whatever the stimulus for release of UII, it is likely 
that the chronic nature of disease is paramount in raising 
blood concentrations. For example, there was no increase 
in UII concentrations in an acute (7 day) right ventricular 
pacing model of heart failure compared to nonpaced control 
animals (Charles et al 2005), but an increase was detected 
by the same laboratory in patients with chronic heart failure 
(Richards et al 2002).
Conclusion
UII has pleiotropic effects within the cardiovascular system, 
with evidence for modulation of cardiac contractility, vascular 
tone, cell proliferation, and cell growth. Recent studies have 
suggested that UII may have a protective effect on the car-
diovascular system, while others implicate UII as a harmful 
mediator. Evidence suggests that the condition of the vascular 
endothelium is a key determinant in how the cardiovascular 
system responds to UII. UII and UT receptors are upregulated 
in a number of cardiovascular disease states, implicating 
the UT receptor system in the pathogenesis and progression 
of disease. Nonpeptide UT receptor antagonists have been 
developed, and their use in animal models of disease point to 
promising therapies for the future. Enthusiasm for this strategy 
is underlined by the signiﬁ  cant reduction in urinary albumin 
excretion that was achieved in macroalbuminuric diabetic 
patients who were treated with the UT receptor antagonist, 
palosuran. Further investigation of UT receptor antagonists and 
their efﬁ  cacy in the treatment of various human cardiovascular 
disease states in which UII is implicated is warranted.
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